Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.46 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.43 |
| ▸ | ESPL1 | Q14674 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1751440 | 0.86 | ALDH1A1 (0.67) | ALDH1A1CYP3A4HSD17B10TSHRGPR35 | |
| SCHEMBL1362507 | 0.86 | TSHR (0.56) | ALDH1A1CYP3A4HSD17B10TSHRGPR35 | |
| SCHEMBL2069936 | 0.81 | ALDH1A1 (0.74) | ALDH1A1CYP3A4HSD17B10GPR35PDE7A | |
| SCHEMBL28683782 | 0.80 | ALDH1A1 (0.72) | ALDH1A1CYP3A4HSD17B10TSHRGPR35 | |
| SCHEMBL6026052 | 0.80 | ALDH1A1 (0.59) | ALDH1A1CYP3A4HSD17B10TSHRGPR35 | |
| SCHEMBL6756419 | 0.80 | ALDH1A1 (0.52) | ALDH1A1CYP3A4HSD17B10TSHRGPR35 | |
| SCHEMBL29710308 | 0.80 | ALDH1A1 (0.52) | ALDH1A1CYP3A4HSD17B10TSHRGPR35 | |
| SCHEMBL2210296 | 0.78 | GPR35 (0.61) | ALDH1A1CYP3A4HSD17B10TSHRGPR35 | |
| SCHEMBL29653777 | 0.78 | GPR35 (0.61) | ALDH1A1CYP3A4HSD17B10TSHRGPR35 | |
| SCHEMBL11404209 | 0.78 | ALDH1A1 (0.63) | ALDH1A1CYP3A4HSD17B10TSHRGPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090477-A1 | HELICASE INHIBITORS AND USES THEREOF | KIMIA THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2025059040-A1 | MUTANT KRAS MODULATORS AND USES THEREOF | NEWAVE PHARMACEUTICAL INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| US-20250017914-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | BLACK DIAMOND THERAPEUTICS, INC. | 2025-01-16 | — | — | US | disclosed |
| WO-2024238872-A2 | ISOINDOLINONE-GLUTARIMIDE ANTIBODY CONJUGATES, AND USES THEREOF | FIREFLY BIO, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| EP-4399210-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | Black Diamond Therapeutics, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-118159537-A | 6-Aza-quinoline derivatives and related uses | 黑钻治疗公司 | 2024-06-07 | — | — | CN | disclosed |
| WO-2023039505-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2023-03-16 | — | — | WO | disclosed |
| WO-2022148422-A1 | BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2022-07-14 | — | — | WO | disclosed |
| EP-2807162-B1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | Bayer Pharma AG (DE) | 2017-06-07 | — | — | EP | disclosed |
| CN-104411707-B | Substituted phenylimidazopyrazoles and their use | 拜耳药业股份公司 | 2017-03-01 | — | — | CN | disclosed |
| EP-2807162-A1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2014-12-03 | — | — | EP | disclosed |
| WO-2013110590-A1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-08-01 | — | — | WO | disclosed |
| US-20130190290-A1 | Substituted phenylimidazopyrazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-25 | — | — | US | disclosed |
| CN-102666507-A | Oxazine derivatives and their use in the treatment of neurological disorders | NOVARTIS AG | 2012-09-12 | — | — | CN | disclosed |
| US-8226758-B2 | Disperse dyes mixtures | DYSTAR COLOURS DEUTSCHLAND GMBH (DE) | 2012-07-24 | — | — | US | disclosed |
| US-8226758-B2 | Disperse dyes mixtures | DYSTAR COLOURS DEUTSCHLAND GMBH (DE) | 2012-07-24 | — | — | US | disclosed |
| CN-102471293-A | Oxazine derivatives and their use as BACE inhibitors for the treatment of neurological disorders | NOVARTIS AG | 2012-05-23 | — | — | CN | disclosed |
| US-20100071589-A1 | DISPERSE DYES MIXTURES | DYSTAR TEXTIFARBEN GMBH & CO. DEUTSCHLAND KG (DE) | 2010-03-25 | — | — | US | disclosed |
| US-20100071589-A1 | DISPERSE DYES MIXTURES | DYSTAR TEXTIFARBEN GMBH & CO. DEUTSCHLAND KG (DE) | 2010-03-25 | — | — | US | disclosed |
| WO-2008074719-A1 | DISPERSE DYES MIXTURES | DYSTAR TEXTILFARBEN GMBH & CO DEUTSCHLAND KG (DE) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250017914-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | TOP2A, TOP2B, UGT2B7 | ALDH1A1 373/4885CYP3A4 89/4885HSD17B10 2728/4885 |
| US-20130190290-A1 | Substituted phenylimidazopyrazoles and their use | VHL, FLT4, FLT1 | ALDH1A1 962/4885CYP3A4 1568/4885HSD17B10 3986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.